KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc

Abstract

• YBX1 is a KMT2D-mediated H3K4me1-binding effector protein and mutation of YBX1 (E121A) disrupts its binding to H3K4me1.

• KMT2D and YBX1 cooperatively promote TNBC proliferation and metastasis by activating c-Myc and SENP1 expression in vitro and in vivo.

• YBX1 is colocalized with H3K4me1 in the c-Myc and SENP1 promoter regions in TNBC cells and increased YBX1 expression predicts a poor prognosis in breast cancer patients.

Keywords

histone H3 lysine 4 mono-methylation (H3K4me1) / lysine methyltransferase 2D (KMT2D) / triple-negative breast cancer (TNBC) / Y-box-binding protein 1 (YBX1)

References

[1] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.

[2] WangYC, LinCH, HuangSP, Chen M, LeeTS. Risk factors for female breast cancer: a population cohort study. Cancers (Basel). 2022;14.

[3] KashyapD, PalD, SharmaR, et al. Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022;2022:9605439.

[4] DerakhshanF, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181-204.

[5] OuXQ, TanYR, XieJD, et al. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer. Drug Resist Update. 2024;73.

[6] TangY, TianW, ZhengS, et al. Dissection of FOXO1-induced LYPLAL1-DT impeding triple-negative breast cancer progression via mediating hnRNPK/beta-catenin complex. Research (Wash D C). 2023;6:0289.

[7] YangX, YanL, DavidsonNE. DNA methylation in breast cancer. Endocr Relat Cancer. 2001;8:115-127.

[8] SzyfM, Pakneshan P, RabbaniSA. DNA methylation and breast cancer. Biochem Pharmacol. 2004;68:1187-1197.

[9] StrahlBD, AllisCD. The language of covalent histone modifications. Nature. 2000;403:41-45.

[10] WeiY, XiaW, ZhangZ, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47:701-706.

[11] YamadaN, Nishida Y, TsutsumidaH, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res. 2008;68:2708-2716.

[12] Garcia-MartinezL, Zhang Y, NakataY, ChanHL, MoreyL. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12:1786.

[13] WuS, LuJ, ZhuH, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024;581:216508.

[14] HuD, GaoX, MorganMA, Herz HM, SmithER, ShilatifardA. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol. 2013;33:4745-4754.

[15] LeeJE, WangC, XuS, et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife. 2013;2:e01503.

[16] WangC, LeeJE, LaiB, et al. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition. Proc Natl Acad Sci U S A. 2016;113:11871-11876.

[17] LaiB, LeeJE, JangY, Wang L, PengW, GeK. MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis. Nucleic Acids Res. 2017;45:6388-6403.

[18] CaoK, Collings CK, MorganMA, et al. An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and pluripotency transition in embryonic stem cells. Sci Adv. 2018;4:eaap8747.

[19] JangY, BrounA, WangC, et al. H3.3K4M destabilizes enhancer H3K4 methyltransferases MLL3/MLL4 and impairs adipose tissue development. Nucleic Acids Res. 2019;47:607-620.

[20] WangSP, TangZ, ChenCW, et al. A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription. Mol Cell. 2017;67:308-321. e306.

[21] AngSY, Uebersohn A, SpencerCI, et al. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation. Development. 2016;143:810-821.

[22] OswaldF, Rodriguez P, GiaimoBD, et al. A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes. Nucleic Acids Res. 2016;44:4703-4720.

[23] ToskaE, Osmanbeyoglu HU, CastelP, et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017;355:1324-1330.

[24] PangL, TianH, GaoX, WangW, WangX, Zhang Z. KMT2D deficiency disturbs the proliferation and cell cycle activity of dental epithelial cell line (LS8) partially via Wnt signaling. Biosci Rep. 2021;41.

[25] SaffieR, ZhouN, RollandD, et al. FBXW7 triggers degradation of KMT2D to favor growth of diffuse large B-cell lymphoma cells. Cancer Res. 2020;80:2498-2511.

[26] LiM, ShiM, XuY, QiuJ, LvQ. Histone methyltransferase KMT2D regulates H3K4 methylation and is involved in the pathogenesis of ovarian cancer. Cell Transplant. 2021;30:9636897211027521.

[27] LvS, WenH, ShanX, et al. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3. Epigenetics. 2019;14:1194-1208.

[28] SunP, WuT, SunX, et al. KMT2D inhibits the growth and metastasis of bladder cancer cells by maintaining the tumor suppressor genes. Biomed Pharmacother. 2019;115:108924.

[29] AlamH, TangM, MaitituohetiM, et al. KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer Cell. 2020;37:599-617.

[30] EvdokimovaV, TognonC, NgT, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15:402-415.

[31] EliseevaIA, KimER, GuryanovSG, Ovchinnikov LP, LyabinDN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc). 2011;76:1402-1433.

[32] KwonE, Todorova K, WangJ, et al. The RNA-binding protein YBX1 regulates epidermal progenitors at a posttranscriptional level. Nat Commun. 2018;9:1734.

[33] El-NaggarAM, Veinotte CJ, ChengH, et al. Translational activation of HIF1alpha by YB-1 promotes sarcoma metastasis. Cancer Cell. 2015;27:682-697.

[34] SomasekharanSP, El-Naggar A, LeprivierG, et al. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. J Cell Biol. 2015;208:913-929.

[35] XuL, LiH, WuL, HuangS. YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer. Oncotarget. 2017;8:65946-65956.

[36] KuwanoM, Shibata T, WatariK, OnoM. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019;110:1536-1543.

[37] HartleyAV, WangB, MundadeR, et al. PRMT5-mediated methylation of YBX1 regulates NF-kappaB activity in colorectal cancer. Sci Rep. 2020;10:15934.

[38] BergmannS, Royer-Pokora B, FietzeE, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005;65:4078-4087.

[39] SutherlandBW, KucabJ, WuJ, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24:4281-4292.

[40] BasakiY, HosoiF, OdaY, et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene. 2007;26:2736-2746.

[41] DaviesAH, ReipasKM, PambidMR, et al. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells. 2014;32:1437-1450.

[42] BasakiY, Taguchi K, IzumiH, et al. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur J Cancer. 2010;46:954-965.

[43] CampbellTM, CastroMAA, de OliveiraKG, PonderBAJ, MeyerKB. ERalpha binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast cancer. Cancer Res. 2018;78:410-421.

[44] ShibataT, Tokunaga E, HattoriS, et al. Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. Oncotarget. 2018;9:37216-37228.

[45] WuL, HuangS, TianW, et al. PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer. Cell Death Discov. 2024;10:7.

[46] BaeS, LeschBJ. H3K4me1 distribution predicts transcription state and poising at promoters. Front Cell Dev Biol. 2020;8:289.

[47] KimJH, SharmaA, DharSS, et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 2014;74:1705-1717.

[48] DharSS, LeeSH, KanPY, et al. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4. Genes Dev. 2012;26:2749-2762.

[49] CaloE, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49:825-837.

[50] HeintzmanND, StuartRK, HonG, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39:311-318.

[51] HeintzmanND, HonGC, HawkinsRD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459:108-112.

[52] PerryJ, ZhaoY. The CW domain, a structural module shared amongst vertebrates, vertebrate-infecting parasites and higher plants. Trends Biochem Sci. 2003;28:576-580.

[53] LiuY, HuangY. Uncovering the mechanistic basis for specific recognition of monomethylated H3K4 by the CW domain of Arabidopsis histone methyltransferase SDG8. J Biol Chem. 2018;293:6470-6481.

[54] LocalA, HuangH, AlbuquerqueCP, et al. Identification of H3K4me1-associated proteins at mammalian enhancers. Nat Genet. 2018;50:73-82.

[55] ChengJ, BlumR, BowmanC, et al. A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers. Mol Cell. 2014;53:979-992.

[56] AnderssonR, Sandelin A, DankoCG. A unified architecture of transcriptional regulatory elements. Trends Genet. 2015;31:426-433.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.